JP6887389B2 - ニーマン・ピック病および他のリソソーム蓄積障害のためのｎｐｃ１のベンゼンスルホンアミド上方制御剤 - Google Patents

ニーマン・ピック病および他のリソソーム蓄積障害のためのｎｐｃ１のベンゼンスルホンアミド上方制御剤 Download PDF

Info

Publication number
JP6887389B2
JP6887389B2 JP2017560888A JP2017560888A JP6887389B2 JP 6887389 B2 JP6887389 B2 JP 6887389B2 JP 2017560888 A JP2017560888 A JP 2017560888A JP 2017560888 A JP2017560888 A JP 2017560888A JP 6887389 B2 JP6887389 B2 JP 6887389B2
Authority
JP
Japan
Prior art keywords
group
disease
groups
substituted
imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017560888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510904A5 (cg-RX-API-DMAC10.html
JP2018510904A (ja
Inventor
テイラー，メルセデス
ローランド カルボ，ラウル
ローランド カルボ，ラウル
ホセ マルガン，ホワン
ホセ マルガン，ホワン
サウスオール，ノエル
ジャン，ウェイ
フェレール−アレグレ，マルク
デダスティ，シーミン
ドランハック，パトリシア
チェン，ファニー
イオアヌ，ヤニス
パトナイック，サマルジット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
United States Department of Health and Human Services
Original Assignee
Icahn School of Medicine at Mount Sinai
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai, United States Department of Health and Human Services filed Critical Icahn School of Medicine at Mount Sinai
Publication of JP2018510904A publication Critical patent/JP2018510904A/ja
Publication of JP2018510904A5 publication Critical patent/JP2018510904A5/ja
Application granted granted Critical
Publication of JP6887389B2 publication Critical patent/JP6887389B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017560888A 2015-02-11 2016-02-11 ニーマン・ピック病および他のリソソーム蓄積障害のためのｎｐｃ１のベンゼンスルホンアミド上方制御剤 Active JP6887389B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562114840P 2015-02-11 2015-02-11
US62/114,840 2015-02-11
PCT/US2016/017504 WO2016130774A1 (en) 2015-02-11 2016-02-11 Benzenesulfonamide upregulators of npc1 for neimann-pick disease and other lysosomal storage disorders

Publications (3)

Publication Number Publication Date
JP2018510904A JP2018510904A (ja) 2018-04-19
JP2018510904A5 JP2018510904A5 (cg-RX-API-DMAC10.html) 2019-03-22
JP6887389B2 true JP6887389B2 (ja) 2021-06-16

Family

ID=56614815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560888A Active JP6887389B2 (ja) 2015-02-11 2016-02-11 ニーマン・ピック病および他のリソソーム蓄積障害のためのｎｐｃ１のベンゼンスルホンアミド上方制御剤

Country Status (8)

Country Link
US (1) US10239830B2 (cg-RX-API-DMAC10.html)
EP (1) EP3256116B1 (cg-RX-API-DMAC10.html)
JP (1) JP6887389B2 (cg-RX-API-DMAC10.html)
CN (1) CN107949380B (cg-RX-API-DMAC10.html)
AU (1) AU2016219231B2 (cg-RX-API-DMAC10.html)
CA (1) CA2976449C (cg-RX-API-DMAC10.html)
IL (2) IL253896B (cg-RX-API-DMAC10.html)
WO (1) WO2016130774A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111289749B (zh) * 2018-12-10 2023-04-14 北京蛋白质组研究中心 C型1类尼曼-匹克蛋白检测物在制备筛查肝细胞癌产品中的应用
WO2021150695A1 (en) * 2020-01-22 2021-07-29 Icahn School Of Medicine At Mount Sinai Constrained n-substituted tetrahydrobenzoazepine sulfonamides as anticancer and neuroprotective agents
WO2022159566A1 (en) 2021-01-21 2022-07-28 Icahn School Of Medicine At Mount Sinai Benzenesulfonamide agonists of trap1 for treating organ fibrosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177447B1 (en) * 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
DE69926148D1 (en) * 1998-11-09 2005-08-18 Black James Foundation Gastrin und cholecystokinin rezeptor ligande
AU2003301443A1 (en) * 2002-10-18 2004-05-04 E.I. Du Pont De Nemours And Company Azolecarboxamide herbicides
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
MX2008013194A (es) 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
US9732067B2 (en) * 2012-06-20 2017-08-15 University Of Kansas Compounds and methods for activating the apoptotic arm of the unfolded protein response
CA2880880C (en) * 2012-08-03 2021-01-26 John Mckew Cyclodextrin for the treatment of lysosomal storage diseases
US20140128352A1 (en) 2012-09-20 2014-05-08 Buck Institute For Research On Aging Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production
EP2823816A1 (en) 2013-07-09 2015-01-14 Tragex Pharma Inhibitors of Neuropilin and use thereof for the treatment of Neuropilin-related diseases

Also Published As

Publication number Publication date
AU2016219231A1 (en) 2017-09-28
US20180044286A1 (en) 2018-02-15
CA2976449A1 (en) 2016-08-18
IL268811A (en) 2019-10-31
AU2016219231A2 (en) 2017-09-28
IL253896B (en) 2019-09-26
CN107949380A (zh) 2018-04-20
EP3256116B1 (en) 2022-08-17
EP3256116A1 (en) 2017-12-20
CN107949380B (zh) 2021-07-06
EP3256116A4 (en) 2018-07-11
WO2016130774A1 (en) 2016-08-18
JP2018510904A (ja) 2018-04-19
CA2976449C (en) 2022-08-09
AU2016219231B2 (en) 2020-08-20
US10239830B2 (en) 2019-03-26
IL253896A0 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
JP6061922B2 (ja) プロテイノパチーの処置方法
TWI558396B (zh) 用於預防和／或治療溶酶體貯積失調之新穎組合物
JP5645918B2 (ja) リソソーム蓄積障害の予防および／または治療方法
ES2628465T3 (es) Derivados deuterados de ivacaftor
JP6204961B2 (ja) 脳アミロイド血管症の治療のための薬理シャペロン
AU2017201599A1 (en) APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF
US9212179B2 (en) Compositions and methods for the treatment of metabolic disorders
CN107949380B (zh) 用于尼曼-匹克病和其他溶酶体贮积症的npc1的苯磺酰胺上调剂
US11278518B2 (en) Methods of treatment using 4-methylumbelliferone and derivatives thereof
KR20240155871A (ko) 소르틸린 의존성 질병의 치료를 위한 아미노산 기반 카바메이트 및/또는 요소
US20170273996A1 (en) Dosing Regimens for Treating And/Or Preventing Cerebral Amyloidoses
US10543282B2 (en) Targeted peptide conjugates
McCabe Chemical Modulation of the NCoR1/RARα Axis for Regulation of Chaperone-Mediated Autophagy in Disease
EP4361165A1 (en) Modulators of sortilin activity

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210518

R150 Certificate of patent or registration of utility model

Ref document number: 6887389

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250